Literature DB >> 31915150

Protection Against Insulin Resistance by Apolipoprotein M/Sphingosine-1-Phosphate.

Makoto Kurano1, Kazuhisa Tsukamoto2,3, Tomo Shimizu4, Hidetoshi Kassai5, Kazuki Nakao5, Atsu Aiba5, Masumi Hara6, Yutaka Yatomi1.   

Abstract

Subjects with low serum HDL cholesterol levels are reported to be susceptible to diabetes, with insulin resistance believed to be the underlying pathological mechanism. Apolipoprotein M (apoM) is a carrier of sphingosine-1-phosphate (S1P), a multifunctional lipid mediator, on HDL, and the pleiotropic effects of HDL are believed to be mediated by S1P. In the current study, we attempted to investigate the potential association between apoM/S1P and insulin resistance. We observed that the serum levels of apoM were lower in patients with type 2 diabetes and that they were negatively correlated with BMI and the insulin resistance index. While deletion of apoM in mice was associated with worsening of insulin resistance, overexpression of apoM was associated with improvement of insulin resistance. Presumably, apoM/S1P exerts its protective effect against insulin resistance by activating insulin signaling pathways, such as the AKT and AMPK pathways, and also by improving the mitochondrial functions through upregulation of SIRT1 protein levels. These actions of apoM/S1P appear to be mediated via activation of S1P1 and/or S1P3. These results suggest that apoM/S1P exerts protective roles against the development of insulin resistance.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID: 31915150     DOI: 10.2337/db19-0811

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  25 in total

1.  Muscle atrophy phenotype gene expression during spaceflight is linked to a metabolic crosstalk in both the liver and the muscle in mice.

Authors:  Geraldine Vitry; Rebecca Finch; Gavin Mcstay; Afshin Behesti; Sébastien Déjean; Tricia Larose; Virginia Wotring; Willian Abraham da Silveira
Journal:  iScience       Date:  2022-09-24

Review 2.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 3.  The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes.

Authors:  W Sean Davidson; Allison L Cooke; Debi K Swertfeger; Amy S Shah
Journal:  Curr Atheroscler Rep       Date:  2021-03-27       Impact factor: 5.113

Review 4.  The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions.

Authors:  Jérôme Robert; Elena Osto; Arnold von Eckardstein
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

Review 5.  Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases.

Authors:  Yelena Drexler; Judith Molina; Alla Mitrofanova; Alessia Fornoni; Sandra Merscher
Journal:  J Am Soc Nephrol       Date:  2020-12-18       Impact factor: 14.978

Review 6.  Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?

Authors:  Christina Christoffersen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

Review 7.  Barrier maintenance by S1P during inflammation and sepsis.

Authors:  Anke C Ziegler; Markus H Gräler
Journal:  Tissue Barriers       Date:  2021-06-21

8.  HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.

Authors:  Anand Rohatgi; Marit Westerterp; Arnold von Eckardstein; Alan Remaley; Kerry-Anne Rye
Journal:  Circulation       Date:  2021-06-07       Impact factor: 39.918

Review 9.  Sphingolipids in metabolic disease: The good, the bad, and the unknown.

Authors:  Christopher D Green; Michael Maceyka; L Ashley Cowart; Sarah Spiegel
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373

10.  Glycation of HDL Polymerizes Apolipoprotein M and Attenuates Its Capacity to Bind to Sphingosine 1-Phosphate.

Authors:  Tamaki Kobayashi; Makoto Kurano; Mai Nanya; Tomo Shimizu; Ryunosuke Ohkawa; Minoru Tozuka; Yutaka Yatomi
Journal:  J Atheroscler Thromb       Date:  2021-01-29       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.